Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 8

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 8
---
 a component of income tax expense.

Please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements to the consolidated financial statements, included elsewhere in this Annual Report on Form 10-K, for a further discussion of our critical accounting policies and estimates.

-73-

The following table sets forth selected consolidated statements of income (loss) data for each of the periods indicated:

    For the Year Ended December 31,

    2024

    2023

    Change

    Change

    (in thousands, except per share amounts)

    $

    %

    Revenues:

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    643,084

    56
    %

    Collaboration and other

    114,019

    98,460

    15,559

    16
    %

    Total revenues

    1,901,979

    1,243,336

    658,643

    53
    %

    Cost and expenses:

    Cost of sales (excluding amortization of in-licensed rights)

    319,099

    150,343

    168,756

    112
    %

    Research and development

    804,522

    877,387

    (72,865
    )

    (8
    )%

    Selling, general and administrative

    557,872

    481,871

    76,001

    16
    %

    Amortization of in-licensed rights

    2,405

    1,559

    846

    54
    %

    Total cost and expenses

    1,683,898

    1,511,160

    172,738

    11
    %

    Operating income (loss)

    218,081

    (267,824
    )

    485,905

    NM*

    Other income (loss), net:

    Other income, net

    42,693

    33,055

    9,638

    29
    %

    Loss on debt extinguishment

    —

    (387,329
    )

    387,329

    (100
    )%

    Gain from sale of Priority Review Voucher

    —

    102,000

    (102